表紙
市場調查報告書
商品編碼
1078236

糙皮病治療的全球市場(2022年∼2029年)

Global Pellagra Treatment Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 185 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球糙皮病治療市場調查,提供市場概要,市場規模和預測,趨勢,成長要素及課題,客戶形勢,藥物·類型·流通管道·各地區的分析,新企業簡介等資訊。

目錄

第1章 糙皮病治療市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 糙皮病治療市場:市場定義和概要

第3章 糙皮病治療市場:摘要整理

  • 各藥物的市場明細
  • 各類型的市場明細
  • 各流通管道的市場明細
  • 各地區的市場明細

第4章 糙皮病治療市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 糙皮病治療市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 未滿足需求

第6章 糙皮病治療市場:COVID-19分析

  • 市場的COVID-19分析
    • COVID-19前的市場方案
    • 目前COVID-19市場方案
    • COVID-19後或未來方案
  • COVID-19的價格變動
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 糙皮病治療市場:各藥物

  • 簡介
  • 各藥物的市場規模分析,及與前一年同期比較成長分析
  • 各藥物的市場魅力指數
    • 尼古丁
    • 煙酰胺

第8章 糙皮病治療市場:各類型

  • 簡介
  • 各類型的市場規模分析,及與前一年同期比較成長分析
  • 各類型的市場魅力指數
    • 一次糙皮病
    • 二次糙皮病

第9章 糙皮病治療市場:各流通管道

  • 簡介
    • 各流通管道的市場規模分析,及與前一年同期比較成長分析
    • 各流通管道的市場魅力指數
  • 醫院藥局
    • 簡介
    • 市場規模分析(2020年∼2029年,及2021年∼2029年)
  • 零售藥局
  • 其他

第10章 糙皮病治療市場:各地區

  • 簡介
    • 各地區的市場規模分析(2020年∼2029年,及2021年∼2029年)
    • 各地區的市場魅力指數
  • 北美
    • 簡介
    • 主要地區具體動態
    • 各藥物的市場規模分析,及與前一年同期比較成長分析
    • 各類型的市場規模分析,及與前一年同期比較成長分析
    • 各流通管道的市場規模分析,及與前一年同期比較成長分析
    • 各國市場規模分析,及與前一年同期比較成長分析
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 各藥物的市場規模分析,及與前一年同期比較成長分析
    • 各類型的市場規模分析,及與前一年同期比較成長分析
    • 各流通管道的市場規模分析,及與前一年同期比較成長分析
    • 各國市場規模分析,及與前一年同期比較成長分析
  • 南美
    • 簡介
    • 主要地區具體動態
    • 各藥物的市場規模分析,及與前一年同期比較成長分析
    • 各類型的市場規模分析,及與前一年同期比較成長分析
    • 各流通管道的市場規模分析,及與前一年同期比較成長分析
    • 各國市場規模分析,及與前一年同期比較成長分析
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 各藥物的市場規模分析,及與前一年同期比較成長分析
    • 各類型的市場規模分析,及與前一年同期比較成長分析
    • 各流通管道的市場規模分析,及與前一年同期比較成長分析
    • 各國市場規模分析,及與前一年同期比較成長分析
  • 中東和非洲
    • 簡介
    • 主要地區具體動態
    • 各藥物的市場規模分析,及與前一年同期比較成長分析
    • 各類型的市場規模分析,及與前一年同期比較成長分析
    • 各流通管道的市場規模分析,及與前一年同期比較成長分析

第11章 糙皮病治療市場:競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準

第12章 糙皮病治療市場:企業簡介概要

  • Western Drugs Ltd.
    • 企業概要
    • 產品系列·種類
    • 主要亮點
    • 財務概要
  • DSM
  • Merck KGaA
  • Foodchem International Corporation
  • Jubilant Life Sciences Limited
  • Lasons
  • Bazayan & Co
  • Resonance Specialties Limited
  • Veer-Chemie

第13章 糙皮病治療市場:DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
目錄
Product Code: DMPH5151

Market Overview

The global pellagra treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Pellagra is a disease caused by a dietary deficiency in niacin (one of the B complex vitamins) or tryptophan (an amino acid).

Market Dynamics

The factors influencing the global pellagra treatment market are the increasing research and development and the increasing prevalence of pellagra.

The increasing research and development is expected to drive the market growth in the forecast period

Pellagra is a disease caused by a dietary deficiency in niacin (one of the B complex vitamins) or tryptophan (an amino acid). The triad of dermatitis, diarrhea, and dementia are the classic clinical features of pellagra, though most people do not have all three. Headache, irritability, poor concentration, apathy and confusion, vertigo, myoclonus, tremor, rigidity, weakness, dysphagia, seizures, and various psychiatric symptoms are all examples of neurologic abnormalities. Patients become disoriented, confused, and delirious as pellagra progresses, then stuporous and comatose, and finally die.

Pellagra can occur in people with Crohn's disease due to niacin deficiency caused by malabsorption and tryptophan wastage combined with increased 5-hydroxyindoleacetic acid excretion in the urine. Pellagra has been linked to infectious colitis and malabsorption caused by intestinal bacterial overgrowth. Niacin, also known as vitamin B3, is a generic name for two compounds: nicotinamide and nicotinic acid. It is required for carbohydrate, fat, protein, alcohol metabolism, drug and reactive oxygen species detoxification, cell signaling, and DNA repair. Niacin-rich foods include tuna fish, chicken, beef, peanuts, mushroom, avocado, and green peas, with recommended daily intakes of 14 mg. At the same time, HIV patients are expected to have higher niacin requirements. Moreover, the WHO recommends taking at least 300 mg nicotinamide in an oral divided daily dose for 3-4 weeks to treat pellagra. Niacin-induced flushing necessitates the use of nicotinamide. General malnutrition and cachexia may necessitate the use of additional dietary supplements.

Limitations associated with pellagra treatment are expected to hamper the market growth

Niacin is probably safe for most people when taken by mouth. Niacin can cause a flushing reaction, a common minor side effect. Side effects include burning, tingling, itching, redness of the face, arms, chest, and headaches. Starting with small doses of niacin and taking 325 mg of aspirin before each dose of niacin can help to reduce the flushing reaction. This reaction usually subsides as the body adjusts to the medication. Alcohol can exacerbate the flushing reaction. When taking niacin, one should stay away from large amounts of alcohol. Concerns have been raised about the risk of stroke in people who take niacin. According to one large study, people who took high doses of niacin had a two-fold higher risk of stroke than those who did not take niacin.

COVID-19 Impact Analysis

Countries worldwide went into lockdown early in the COVID-19 pandemic, shutting down or reducing transport within and between them. This impacted medicine manufacturing, supply, and distribution, causing global medicines supply chain bottlenecks. Some medicines used in COVID-19 patients have also seen an increase in demand. For instance, niacin is a component of NAD and NADP, important during chronic systemic inflammation. Increased levels of NAD+ are required to treat a wide range of pathophysiological conditions because it acts as a coenzyme in various metabolic pathways. NAD+ is produced in the early stages of inflammation and has immunomodulatory properties, lowering pro-inflammatory cytokines such as IL-1, IL-6, and TNF-.According to new research, targeting IL-6 may help control the inflammatory storm in COVID-19 patients. Niacin could be used as an adjunct treatment for COVID-19 patients because of its lung-protective and immune-strengthening properties. Hence, covid-19 is expected to positively impact the market with the rise in demand for niacin.

Segment Analysis

Primary pellagra is expected to dominate the market growth

Diets low in niacin or tryptophan cause primary pellagra. Because tryptophan is converted to niacin in the body, a lack of it can result in a niacin deficiency. Primary pellagra is common in developing countries where corn (maize) is a major food source or aftermath of long-term disasters such as famine or war. Corn is high in niacin, but it is locked up in a bound form that can only be accessed with alkaline solutions, and corn proteins are low in tryptophan. Pellagra is still endemic in India, China, and parts of Africa.

Dietary and lifestyle changes and a niacin or nicotinamide supplement treat primary pellagra. Nicotinamide is another form of Vitamin B3 used to treat pellagra in its early stages. When a disease is detected early on, it is possible to recover completely within a few days of starting treatment. On the other hand, skin improvement may take some time (usually a few months). When pellagra is left untreated, it can lead to death in as little as 4-5 years.

Geographical Analysis

North America region is expected to hold the largest market share in the global pellagra treatment market

The growing prevalence of pellagra and increasing research and development in this region is expected to drive the market growth.

Pellagra (a niacin deficiency disease) claimed more than 100,000 lives in the United States alone, affecting more than 3 million people. Pellagra reached epidemic proportions in the American South in the early 1900s. Pellagra infected over 3 million Americans during that time, resulting in over 100,000 deaths, but the epidemic ended after dietary niacin fortification. Hence, with pellagra's increasing prevalence, the demand for its treatment increased. And is expected to boost the market growth in North America region.

Competitive Landscape

With mergers, acquisitions, and product launches, the global pellagra treatment market is moderately competitive. Some of the key players in the market are DSM, Merck KGaA, Foodchem International Corporation, Jubilant Life Sciences Limited, Western Drugs Ltd., Lasons, Bazayan & Co, Resonance Specialties Limited, Veer-Chemie

Western Drugs Ltd.

Overview: Western Drugs Ltd. is a leading manufacturer of Niacin (Nicotinic Acid) and Niacinamide. The company was founded in 1989 and is headquartered in India.

Product Portfolio: Vitamin B3 Niacin (Nicotinic Acid) is a nutrient additive used in food, feed, and pharmaceutical/nutritional products. It is an essential B complex vitamin, also known as Vitamin B3, with various uses. It is available in powder and granular form.

Why Purchase the Report?

Visualize the composition of the global pellagra treatment market segmentation by drug, type, and distribution channel, highlighting the key commercial assets and players.

identify commercial opportunities in global pellagra treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global pellagra treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global pellagra treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Pellagra Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Pellagra Treatment Market- Market Definition and Overview

3. Pellagra Treatment Market- Executive Summary

  • 3.1. Market Snippet By Drug
  • 3.2. Market Snippet By Type
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet By Region

4. Pellagra Treatment Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The increasing research and development
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with pellagra treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Pellagra Treatment Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Pellagra Treatment Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Pellagra Treatment Market- By Drug

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
  • 7.3. Market Attractiveness Index, By Drug
    • 7.3.1. Niacin
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.3.2. Niacinamide

8. Pellagra Treatment Market-By Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 8.3. Market Attractiveness Index, By Type
    • 8.3.1. Primary Pellagra
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3.2. Secondary Pellagra

9. Pellagra Treatment Market- By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Other

10. Pellagra Treatment Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Pellagra Treatment Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Pellagra Treatment Market- Company Profiles

  • 12.1. Western Drugs Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. DSM
  • 12.3. Merck KGaA
  • 12.4. Foodchem International Corporation
  • 12.5. Jubilant Life Sciences Limited
  • 12.6. Lasons
  • 12.7. Bazayan & Co
  • 12.8. Resonance Specialties Limited
  • 12.9. Veer-Chemie

LIST NOT EXHAUSTIVE

13. Pellagra Treatment Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us